

1 **CD4+ and CD8+ T cell and antibody correlates of protection against**
2 **Delta vaccine breakthrough infection: A nested case-control study**
3 **within the PITCH study**

4 Isabel Neale^{1,2,3}, Mohammad Ali^{1,2,3}, Barbara Kronsteiner^{1,2}, Stephanie Longet^{4,5},
5 Priyanka Abraham^{1,2}, Alexandra S. Deeks^{1,6}, Anthony Brown¹, Shona C. Moore⁷,
6 Lizzie Stafford⁵, Susan L. Dobson⁷, Megan Plowright^{8,9}, Thomas A.H. Newman^{8,9},
7 Mary Y Wu¹⁰, Crick COVID Immunity Pipeline^{10,11}, Edward J Carr¹¹, Rupert
8 Beale^{11,12}, Ashley D Otter¹³, Susan Hopkins¹⁴, Victoria Hall^{14,15}, Adriana
9 Tomic^{16,17,18,19}, Rebecca P. Payne²⁰, Eleanor Barnes^{1,6,21,22}, Alex Richter^{23,24},
10 Christopher J.A. Duncan^{20,25}, Lance Turtle^{7,26}, Thushan I. de Silva^{8,9}, Miles Carroll^{4,5},
11 Teresa Lambe^{19,27}†, Paul Klenerman^{1,6,21,22}†* and Susanna Dunachie^{1,2,3,6}†* on
12 behalf of the PITCH Consortium

- 13 1. Peter Medawar Building for Pathogen Research, Nuffield Department of Clinical
14 Medicine, University of Oxford, UK
15 2. NDM Centre For Global Health Research, Nuffield Department of Clinical
16 Medicine, University of Oxford, UK
17 3. Mahidol-Oxford Tropical Medicine Research Unit, Bangkok, Thailand
18 4. Pandemic Sciences Institute, Nuffield Department of Medicine, University of
19 Oxford, UK
20 5. Wellcome Centre for Human Genetics, Nuffield Department of Medicine,
21 University of Oxford, UK
22 6. Oxford University Hospitals NHS Foundation Trust, Oxford, UK
23 7. NIHR Health Protection Research Unit in Emerging and Zoonotic Infections,
24 Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool,
25 UK
26 8. Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK
27 9. Department of Infection, Immunity and Cardiovascular Disease, University of
28 Sheffield, UK
29 10. Covid Surveillance Unit, The Francis Crick Institute, London, UK
30 11. The Francis Crick Institute, London, UK
31 12. UCL Department of Renal Medicine, Royal Free Hospital, London, UK
32 13. UK Health Security Agency, Porton Down, UK
33 14. UK Health Security Agency, London, SE1 8UG, UK
34 15. UK Health Security Agency, London, NW9 5EQ, UK
35 16. National Emerging Infectious Diseases Laboratories, Boston University, Boston,
36 MA, USA
37 17. Department of Microbiology, Boston University School of Medicine, Boston, MA,
38 USA
39 18. Department of Biomedical Engineering, Boston University, Boston, MA, USA
40 19. Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford,
41 UK

- 42 20. Translational and Clinical Research Institute Immunity and Inflammation Theme,
43 Newcastle University, Newcastle, UK
44 21. Translational Gastroenterology Unit, University of Oxford, Oxford, UK
45 22. NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK
46 23. Institute of Immunology and Immunotherapy, College of Medical and Dental
47 Science, University of Birmingham, Birmingham, UK
48 24. University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK
49 25. Department of Infection and Tropical Medicine, Newcastle upon Tyne Hospitals
50 NHS Foundation Trust, Newcastle, UK
51 26. Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK
52 27. Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University
53 of Oxford, Oxford, UK

54 †Senior author

55 *Corresponding authors:

56 Susanna Dunachie, Peter Medawar Building for Pathogen Research, University of
57 Oxford, OX1 3SY, UK. susie.dunachie@ndm.ox.ac.uk

58 Paul Klenerman, Peter Medawar Building for Pathogen Research, University of
59 Oxford, Oxford OX1 3SY, UK. paul.klenerman@ndm.ox.ac.uk

60 Secondary author list is included in the supplement.

61 **ABSTRACT**

62 T cell correlates of protection against SARS-CoV-2 infection after vaccination
63 ('vaccine breakthrough') are incompletely defined, especially the specific
64 contributions of CD4+ and CD8+ T cells. We studied 279 volunteers in the Protective
65 Immunity from T Cells in Healthcare Workers (PITCH) UK study, including 32 cases
66 (with SARS-CoV-2 positive testing after two vaccine doses during the Delta-
67 dominant era) and 247 controls (no positive test nor anti-nucleocapsid
68 seroconversion during this period). 28 days after second vaccination, before all
69 breakthroughs occurred, cases had lower ancestral S- and RBD-specific
70 immunoglobulin G titres and S1- and S2-specific T cell interferon gamma (IFN γ)
71 responses compared with controls. In a subset of matched cases and controls,
72 cases had lower CD4+ and CD8+ IFN γ and tumour necrosis factor responses to
73 Delta S peptides with reduced CD8+ responses to Delta versus ancestral peptides
74 compared with controls. Our findings support a protective role for T cells against
75 Delta breakthrough infection.

76 INTRODUCTION

77 Vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
78 has been a crucial control strategy for the current COVID-19 pandemic. Although
79 new SARS-CoV-2 variants continue to emerge and cause infection, vaccine
80 protection against severe COVID-19 remains high for otherwise healthy individuals
81 (Collie et al., 2022; Tartof et al., 2021). Nonetheless, infection or re-infection after a
82 two-dose primary vaccination course, so-called ‘vaccine breakthrough’, occurred
83 during the emergence and spread of variants of concern (VOC). As a result, booster
84 (third) doses have been made available to all adults in many countries including the
85 UK (UK Health Security Agency, 2022).

86 Understanding correlates of protection (CoP) against infection with SARS-CoV-2
87 could optimise delivery of current vaccines by informing boosting schedules and
88 identifying individuals with suboptimal responses to vaccination. Identification of CoP
89 could further facilitate licencing of modified or new vaccines based on
90 immunogenicity and safety data rather than efficacy data (Feng et al., 2021),
91 allowing new vaccines to more readily enter the marketplace.

92 Evidence supports a number of humoral correlates of protection against infection
93 with SARS-CoV-2. Neutralising antibody (NAb) titres after vaccination correlate with
94 vaccine efficacy and protection from infection in trials (Earle et al., 2021; Feng et al.,
95 2021; Gilbert et al., 2022; Khoury et al., 2021) and NABs from prior infection with
96 ancestral variant are associated with protection against infection with ancestral
97 (Addetia et al., 2020) and Alpha (Atti et al., 2022) variants. NABs against SARS-CoV-
98 2 are lower in the peri-infection period in those who experience Alpha vaccine
99 breakthrough (Bergwerk et al., 2021), and are lower at diagnosis in those who
100 experience Delta vaccine breakthrough (Chau et al., 2021) compared with uninfected
101 controls. Anti-ancestral spike (S) and receptor binding domain (RBD)
102 immunoglobulin G (IgG) titres also correlate with protection from infection with the
103 Alpha variant (Feng et al., 2021) and Delta variant (Aldridge et al., 2022; Smoot et
104 al., 2022; Wei et al., 2022) after vaccination. Ancestral variant RBD-specific memory
105 B cell responses were lower in Delta breakthrough cases at the point of diagnosis
106 compared to uninfected close contacts (Tay et al., 2022). Levels of serum anti-Spike
107 and anti-RBD IgA 2-4 weeks after second dose of BNT162b2 vaccine were also
108 lower in those who experienced subsequent Alpha or Gamma vaccine breakthrough
109 compared to those who remained uninfected (Sheikh-Mohamed et al., 2022).

110 T cells play an important role in control of SARS-CoV-2 infection and in reducing
111 disease severity upon infection (Kedzierska and Thomas, 2022; Moss, 2022). In
112 primary infection, strong SARS-CoV-2 specific CD4+ and CD8+ T cell responses are
113 associated with reduced disease severity (Rydyznski Moderbacher et al., 2020).
114 Several studies have demonstrated that spike-specific T cell responses are largely

115 maintained against VOC (Gao et al., 2022; Moore et al., 2022; Payne et al., 2021;
116 Skelly et al., 2021; Tarke et al., 2022), despite evasion of antibody responses (Cele
117 et al., 2022; Planas et al., 2021; Zhou et al., 2021). This supports T cells contributing
118 to the continued effectiveness of vaccines against severe disease.

119 However, identifying a clear role for T cells in preventing infection is difficult due to
120 the lack of sensitive, scalable T cell assays, and potential confounding effects of
121 antibody responses (Kedzierska and Thomas, 2022; Kent et al., 2022). Nonetheless,
122 an increasing number of reports indicate that T cells are likely to be important in
123 protection against SARS-CoV-2 infection. Unvaccinated individuals who are exposed
124 to SARS-CoV-2 but remain antibody and PCR-negative show T cell responses
125 (Ogbe et al., 2021), and further studies demonstrate that pre-existing, cross-reactive
126 T cell responses are associated with protection from overt infection (Kundu et al.,
127 2022; Swadling et al., 2022). In an unvaccinated cohort study, seronegative
128 individuals with detectable SARS-CoV-2-specific T cell responses had a lower risk of
129 subsequent infection than seronegative individuals without positive T cell responses
130 (Molodtsov et al., 2022). More recently, higher whole-blood interferon gamma (IFN γ)
131 responses to SARS-CoV-2 peptides among individuals who had received at least
132 one vaccine dose were associated with a lower risk of breakthrough infection over
133 the subsequent 6-month period (Scurr et al., 2022). There are also indications that
134 the combination of cellular and humoral responses may be important in protecting
135 against Delta and Omicron breakthrough infection. The combination of high NAb titre
136 and high S1-specific IFN γ responses is associated with protection against
137 breakthrough (Almendro-Vázquez et al., 2022). Also, 'high responders' to
138 vaccination, characterised by high antibody, enriched CD4 $^{+}$ and CD8 $^{+}$ central
139 memory 1, and durable CD8 $^{+}$ T cell responses, are more protected against
140 symptomatic breakthrough compared to 'low responders', characterised by low
141 antibody responses and more prevalent T effector memory 2 responses (Brasu et
142 al., 2022). Although these data indicate an important role for T cells, it is still unclear
143 to what extent T cell protection is mediated by CD4 $^{+}$ versus CD8 $^{+}$ T cells, as in
144 many studies only total T cell responses are investigated. However, depletion of
145 vaccine-induced CD8 $^{+}$ T cells in rhesus macaques and subsequent challenge
146 demonstrated that CD8 $^{+}$ T cells contribute to vaccine protection against SARS-CoV-
147 2 replication in this model (Liu et al., 2022). Therefore, further research is needed to
148 define possible T cell CoP against SARS-CoV-2 infection, in particular the
149 contributions of CD4 $^{+}$ and CD8 $^{+}$ T cells to protection in humans.

150 Large-scale prospective studies with recruitment and sampling of individuals prior to
151 breakthrough give opportunity to better understand possible T cell CoP against
152 SARS-CoV-2 (Kent et al., 2022). The Protective Immunity from T Cells in Healthcare
153 workers (PITCH) consortium is a prospective longitudinal cohort study of cellular
154 immune responses to vaccination and infection in healthcare workers (HCWs) in the
155 UK (<http://www.pitch-study.org/>), aligned with the wider SARS-CoV-2 immunity &

156 reinfection evaluation (SIREN) study (Hall et al., 2022; Hall et al., 2021a; Hall et al.,
157 2021b). The PITCH cohort demonstrated that an extended interval between first and
158 second dose of the BNT162b2 vaccine was associated with higher NAb and anti-S
159 IgG binding titre and lower S-specific T cell response magnitude but higher
160 interleukin-2 (IL-2) production compared to a shorter interval (Payne et al., 2021),
161 findings which were also demonstrated in a separate study of older adults (Parry et
162 al., 2022). The PITCH cohort includes individuals studied from April 2020 onwards,
163 with data from pre-vaccination through to after the fourth vaccine dose, allowing
164 sampling of well-characterised participants who subsequently experienced infection.
165 The first vaccine breakthrough case in a PITCH participant was reported on the 10th
166 June 2021, at which time, Delta was the predominant variant circulating in the UK
167 (UK Health Security Agency, 2021). A further 35 reports of vaccine breakthrough
168 occurred in the cohort before the first Omicron cases were reported in the UK on 27th
169 November 2021 (Department of Health and Social Care, 2021). This offers an
170 opportunity to use samples stored from before breakthrough infection to investigate
171 CoP against infection after vaccination.

172 In the current study, we conducted a case-control study within the PITCH framework,
173 using cases who reported infection during the Delta-dominant era in the UK, and
174 controls who did not experience vaccine breakthrough during this time. Cellular and
175 humoral immunity at the timepoint 28 days after the second vaccine dose (V2+28)
176 was studied using an unmatched overall design in order to investigate whether peak
177 post-vaccination responses are associated with subsequent breakthrough infection,
178 irrespective of factors which may influence the level of response. A subset of cases
179 and matched controls were selected for more detailed analysis of cellular immunity.
180 We observed lower S- and RBD-specific IgG binding titre and lower S1- and S2-
181 specific T cell responses by IFN γ ELISpot assay in cases compared with controls at
182 V2+28. Using intracellular cytokine staining (ICS), we observed lower CD4+ and
183 CD8+ IFN γ and tumour necrosis factor (TNF) responses to Delta peptides among
184 cases compared with matched controls.

185 RESULTS

186 *Breakthrough infections during the Delta predominant era in the UK*

187 Between 10th June and 27th November 2021, there were 36 self-reports of vaccine
188 breakthrough (positive polymerase chain reaction (PCR) or lateral flow device (LFD)
189 test for SARS-CoV-2 >14 days after second vaccine dose and <7 days after third
190 vaccine dose) in the PITCH cohort. These participants had been vaccinated with two
191 doses of SARS-CoV-2 vaccine between 6th January and 17th July 2021. 26 (72.2%)
192 participants received BNT162b2 (Pfizer/BioNTech) and 10 (27.8%) received
193 AZD1222 (Oxford/AstraZeneca) (Table 1). The median age of vaccine breakthrough
194 cases was 43 (interquartile range [IQR] 31.5-49; range 22-72), 30 (83.3%) cases
195 were female, and the majority (93.3%) of cases were of white ethnicity, reflecting the
196 demographics of the underlying SIREN and PITCH study cohorts (Hall et al., 2021b;
197 Payne et al., 2021). The median time between second vaccine dose and positive
198 PCR or LFD test was 156 days (IQR 123.8-180.5; range 48-253).

199 *Vaccine breakthrough is more common in individuals without history of previous* 200 *infection*

201 As expected, previous SARS-CoV-2 infection contributed to protection against
202 further infection. Comparison of demographic characteristics of all breakthrough
203 infection cases (n=36) with controls, defined as eligible individuals in PITCH who did
204 not report a positive PCR or LFD by, and were still enrolled at, the 27th November
205 2021 or their third vaccine dose (n=378), showed that the odds of vaccine
206 breakthrough was higher among those previously infection-naïve compared to those
207 previously infected with SARS-CoV-2 before vaccination (p=0.0009, Table 1,
208 Supplementary Figure S1). No significant association was found between odds of
209 vaccine breakthrough infection and age, sex, body mass index (BMI), ethnicity or
210 vaccine type. All cases sampled at V2+28 (n=32) were then selected for a case-
211 control study with controls (n=247) being those who had been sampled at the V2+28
212 timepoint and who did not report vaccine breakthrough or show evidence of anti-
213 nucleocapsid (N) IgG seroconversion during the period of interest (Figure 1A).

214 *Cases have lower humoral and cellular responses than controls at V2+28*

215 Comparing all cases with a V2+28 sample to all available controls, cases had lower
216 anti-S (p=0.001), -RBD (p=0.003) and -N (p=0.002) IgG binding titre compared with
217 controls (Figure 1B, C). In a subset of cases (n=21) and controls (n=41), NAb titre
218 against ancestral and Delta variants was measured (Figure 1D). No difference in
219 median NAb titre against ancestral variant was detected between cases and
220 controls, although the sample size was small. There was a trend for lower median

221 NAb titre against the Delta variant among cases compared to controls ($p=0.071$).
222 Both cases and controls displayed a reduction in NAb titre to Delta compared to
223 ancestral virus (both $p<0.001$). Cases also demonstrated lower ancestral S1-
224 ($p=0.016$), S2- ($p=0.028$) and total S- ($p=0.014$) specific IFN γ ELISpot responses
225 compared to controls at the V2+28 timepoint (Figure 1E). Previous infection was a
226 strong determinant of both IgG and IFN γ responses (Supplementary Figure S2 A-G).
227 In a subset of individuals where cell availability permitted, IFN γ responses to peptide
228 pools representing Delta S1 and S2 were assessed (Supplementary Figure S2 H-J).
229 However, no difference was detected in responses between cases and controls,
230 possibly due to the small sample size in this analysis.

231 There was weak correlation between individual anti-S IgG titre and total S IFN γ
232 responses (Figure 1F). To investigate the combined effect of antibody and cellular
233 responses on the risk of vaccine breakthrough, individuals were categorised as
234 having 'High' or 'Low' anti-S IgG and S-specific IFN γ responses on the basis of
235 whether the response was above or below the median, such that individuals were
236 divided into four categories (Figure 1G). The proportion of individuals experiencing
237 vaccine breakthrough was significantly different between categories (Fisher's exact
238 test, $p=0.003$). The proportion of those experiencing vaccine breakthrough was
239 lowest among those with High IgG and High IFN γ responses, significantly lower than
240 those with Low IgG and Low IFN γ responses (pairwise Fisher's exact test, adjusted
241 $p=0.005$). Those with either High IgG and Low IFN γ responses or Low IgG and High
242 IFN γ responses had intermediate risk of breakthrough, although there was a trend
243 for a difference between those with Low IgG and High IFN γ responses and those
244 with High IgG and High IFN γ responses (adjusted $p=0.067$), highlighting the
245 importance of the IgG response.

246 *Cases have lower S-specific T cell responses to Delta peptides compared to controls*
247 *at V2+28*

248 In a subset of cases and matched controls, all of whom were SARS-CoV-2 infection-
249 naïve at vaccination, further analysis of cellular CoP was undertaken. Ancestral and
250 Delta S-specific memory B cell frequency was compared in a subset of cases ($n=10$)
251 and matched controls ($n=11$) where peripheral blood mononuclear cell (PBMC)
252 samples were available (Figure 2A, B). There was a trend for lower Delta S-specific
253 memory B cell frequency among cases compared to controls ($p=0.088$). However,
254 there was high variation among controls and an outlier among cases, meaning that
255 these data do not allow a conclusion to be drawn.

256 CD4+ and CD8+ T cell responses were further investigated by intracellular cytokine
257 staining (ICS) in a subset of cases and matched controls where PBMC were
258 available ($n=12$ per group). For CD4+ responses, there was a trend for lower
259 frequency of IFN γ and TNF expressing cells in cases compared with controls, for

260 both ancestral and Delta S peptide pools (Figure 2C). This difference was significant
261 for TNF in response to ancestral S ($p=0.004$), and IFN γ ($p=0.010$) and TNF
262 ($p=0.030$) in response to Delta S peptides. There was high variability in frequency of
263 IL-2 expressing CD4+ T cells among cases and controls, with no difference detected
264 in median frequency between groups. Across CD8+ T cell responses, there was a
265 similar pattern, with a difference detected in frequency of IFN γ ($p=0.034$) and TNF
266 ($p=0.013$) expressing cells in response to Delta S peptides (Figure 2D). This
267 difference appeared to be driven by a reduced response among cases to Delta
268 peptides compared to ancestral peptides, which was not present in controls. CD8+
269 IL-2 responses appeared to be slightly higher in cases compared to controls in
270 response to ancestral S (Figure 2D, $p=0.046$). However, overall CD8+ IL-2
271 responses were very low and this trend appeared to be driven by one outlier with
272 very high CD8+ responses across all cytokines.

273 Across IFN γ and TNF responses, on average over half of the response was
274 contributed by CD4+ T cells, however there was substantial variation between
275 individuals (Supplementary Figure S3A, B). A higher proportion of the TNF response
276 to Delta peptide pools was contributed by CD4+ T cells among cases compared to
277 controls ($p=0.028$). CD4+ T cells contributed almost all of the IL-2 response to
278 ancestral and Delta S peptide pools across the majority of cases and controls
279 (Supplementary Figure S3C). Polyfunctionality analysis indicated that cases had a
280 lower frequency of TNF/IFN γ + double positive CD4+ and CD8+ T cells in response
281 to Delta peptides compared with controls (Supplementary Figure S3E, G). There was
282 also a trend for lower frequency of TNF+ single positive CD4+ and CD8+ T cells
283 among cases compared to controls (Supplementary Figure S3 D-G).

284 DISCUSSION

285 This study examines potential CoP against SARS-CoV-2 breakthrough infection after
286 two vaccine doses during the Delta-predominant era in the UK. Breakthrough
287 infection was less likely in those with previous SARS-CoV-2 infection compared with
288 those previously infection-naïve, consistent with other reports (Dhumal et al., 2022;
289 Torres et al., 2022a). Cases showed lower anti-S and -RBD IgG binding titre, as well
290 as lower S1- and S2-specific IFN γ T cell responses by ELISpot assay, compared
291 with controls. In further analysis by ICS, lower CD4+ and CD8+ IFN γ and TNF
292 responses to Delta S peptide pools were found among cases compared to controls.
293 Our detailed look at spike-specific T cell function with sensitive assays provides
294 further evidence of T cell CoP to add to established serological CoP from large
295 studies of humoral function.

296 Our finding that anti-S and -RBD IgG binding titres differ between those who go on to
297 experience breakthrough and those who do not experience overt infection is
298 consistent with a number of other reports which previously demonstrated an
299 association between these parameters and risk of breakthrough infection (Aldridge et
300 al., 2022; Feng et al., 2021; Wei et al., 2022). The SIREN study is also well placed to
301 look at serological CoP against reinfection in a large cohort of HCWs which includes
302 several cases and controls from this study. SIREN recently reported that anti-S
303 antibody levels and NAb titres correlated with protection against reinfection during
304 the Alpha wave, prior to vaccination (Atti et al., 2022).

305 In this study, vaccine breakthrough was associated with lower IFN γ T cell responses
306 by ELISpot, and lower CD4+ and CD8+ IFN γ and TNF responses to Delta peptides
307 in ICS, even using a modest sample size. There are increasing reports indicating an
308 important role for T cell CoP alongside serological CoP (Almendro-Vázquez et al.,
309 2022; Molodtsov et al., 2022; Scurr et al., 2022). Our findings using the IFN γ ELISpot
310 assay help to validate these reports. Our more detailed findings using ICS support a
311 role for both CD4+ and CD8+ T cells in protecting against susceptibility to overt
312 infection with the Delta variant. The apparent drop in CD8+ IFN γ and TNF responses
313 to Delta peptides compared with ancestral peptides among cases was particularly
314 striking and suggests a role for variant-specific CD8+ T cells in protection against
315 infection with the Delta variant. Previous studies in a rhesus macaque model support
316 a role for CD8+ T cell responses in protection against re-challenge in the context of
317 waning antibody levels (McMahan et al., 2021), and a direct role in vaccine-induced
318 protection against SARS-CoV-2 replication (Liu et al., 2022). In addition, infection-
319 naïve vaccinees with high antibody responses have enriched CD4+ and CD8+
320 central memory 1 cell responses and durable CD8+ T cell responses to ancestral
321 and VOC S peptides compared to those with low antibody responses, and are
322 protected against symptomatic breakthrough infection with Delta or Omicron (Brasu
323 et al., 2022). Virus-specific CD8+ T cells are associated with protection against

324 infection with other viral pathogens. For example, in the context of influenza A virus
325 (IAV) epidemics, each fold increase in pre-existing H3N2- or seasonal H1N1-specific
326 CD8+ T cell response is associated with reduced odds of infection with H3N2 or
327 pandemic H1N1 IAV respectively (Tsang et al., 2022). IFN γ +IL2- CD8+ T cells
328 specific for conserved IAV core protein epitopes are also associated with protection
329 against symptomatic disease caused by pandemic H1N1 IAV (Sridhar et al., 2013).
330 Several human studies investigating immune responses around the time of SARS-
331 CoV-2 breakthrough infection have not identified differences in T cell responses
332 between cases and controls, but have identified differences in terms of NAb titre
333 (Park et al., 2022; Rovida et al., 2021) and memory B cell responses (Tay et al.,
334 2022). The difference in results between these studies and our study may be due to
335 different timing of sampling and/or SARS-CoV-2 variant.

336 Our study focused on the Delta wave of infections in the UK, during a time at which
337 the study participants had received two vaccine doses. However, the Delta variant
338 has been largely displaced by Omicron in the UK and globally, and in the UK a third
339 SARS-CoV-2 vaccine dose has been recommended to all adults (UK Health Security
340 Agency, 2022) with further doses for those at increased risk and HCWs. The
341 generalisability of the findings of this study to Omicron breakthroughs occurring after
342 two or three vaccine doses needs further evaluation. Studies of CoP against
343 Omicron have reported mixed results. A study investigating breakthrough after two
344 vaccine doses found that there was no difference in anti-RBD titre between cases
345 who subsequently experienced Omicron breakthrough and controls (Smoot et al.,
346 2022). Other studies did not identify differences in anti-S IgG titre (Stærke et al.,
347 2022), anti-RBD IgG titre, Omicron NAb titre or T cell IFN γ responses (Torres et al.,
348 2022b) after a third vaccine dose between those who subsequently experienced
349 Omicron breakthrough and those who did not. However, others have reported that
350 low anti-S Ab titre and weak neutralisation post-third dose is associated with higher
351 risk of breakthrough (Mohlendick et al., 2022). In the peri-infection period, low pre-
352 infection anti-S IgG titre is associated with breakthrough (Nunes et al., 2022);
353 however, it has also been shown that Omicron breakthrough can occur in those with
354 high NAb titres (Roeder et al., 2022).

355 **Limitations**

356 Important limitations are as follows. (i) The sample size for cases is relatively small,
357 despite follow up of a large number of individuals in the overall PITCH consortium,
358 because breakthrough infection during this time (pre-Omicron) was still relatively
359 rare. We used the maximum sample size available for this case-control study for
360 each assay type, however, the small number of cases means there was inadequate
361 power to conduct a fully adjusted analysis of the effect of humoral and cellular
362 responses on odds of vaccine breakthrough using logistic regression. This means
363 there may be some confounding in our analysis, for example, due to previous

364 infection. However, non-mechanistic CoP are still useful. There are unfortunately no
365 further stored PBMC samples available for analysis. (ii) Sequence information was
366 not available so we were unable to confirm whether these breakthrough infections
367 were attributable to the Delta variant. However, during the period in which the
368 infections occurred, Delta was the predominant variant in the UK, causing $\geq 89.9\%$ of
369 genotyped infections throughout this time. This approach using the timing of infection
370 to indicate which variant is likely the cause of infection is in line with approaches
371 used in other studies (Collie et al., 2022). (iii) Our study was not designed to explore
372 specific co-morbidities, particularly immunosuppression, as risk factors for
373 breakthrough infection (Green et al., 2022; Selvavinayagam et al., 2022). This is
374 addressed in the subsequent VIBRANT study (<https://vibrant-research-study.org/>).
375 (iv) All observational studies carry the risk of bias. Adherence to LFD and PCR
376 testing recommendations was not monitored within PITCH, thus there may be some
377 mis-classification of controls. Although serology from later follow up points was used
378 to confirm as far as possible that controls were not infected during the period of
379 interest, up to 60% of vaccinated individuals may not undergo anti-N seroconversion
380 upon infection (Follmann et al., 2022). It is likely there were differences in exposure
381 to SARS-CoV-2 between individuals dependent on their exact HCW role, for
382 example, seeing more than one COVID-19 patient per day has previously been
383 associated with a higher risk of infection among HCWs (Feng et al., 2021); however,
384 this information was not available for us to take in to account in analysis. (v) We did
385 not investigate mucosal immunity in this study, as mucosal samples were not
386 obtained from PITCH participants at that time. Mucosal immune responses do not
387 necessarily correlate with responses in the peripheral circulation (Lim et al., 2022),
388 and may play an important role in protection against SARS-CoV-2 infection,
389 particularly in individuals with hybrid immunity (Russell and Mestecky, 2022).
390 Ongoing PITCH research now incorporates measurement of mucosal immunity.
391 Nonetheless, this study has several strengths, primarily that the PITCH cohort is very
392 well characterised, and the prospective nature of the study allowed investigation at a
393 pre-specified timepoint reflecting peak vaccine responses, prior to infection.

394 Questions remain regarding the mechanism of action of these putative T cell CoP.
395 CD8+ T cells may contribute to control of replication after infection, as demonstrated
396 in a rhesus macaque model (Liu et al., 2022). CD4+ T cells are important for
397 providing T cell help to support CD8+ T cells and for generation of Ab responses.
398 There may also be a role for HLA type and which epitopes are immunodominant in
399 different individuals. For example, it has been shown that there is an association
400 between the HLA-DQB1*06 allele and higher anti-RBD IgG titre after vaccination
401 with AZD1222, and that this may play a role in protection from breakthrough infection
402 with ancestral and Alpha strains (Mentzer et al., 2022).

403 Overall, our study supports a role for T cell responses alongside antibody responses
404 in protection against detectable infection during the period after double vaccination,

405 over which antibody responses have been shown to wane (Levin et al., 2021; Moore
406 et al., 2022; Naaber et al., 2021). Moreover, our results suggest a potential role for
407 variant-specific CD8+ T cell responses. Development of sensitive, quantitative T cell
408 assays that can be used at scale in large cohorts in a range of settings will allow
409 further integrated study of humoral and cellular adaptive immunity and inform
410 vaccine surveillance and effectiveness monitoring.

411 **METHODS**

412 *Study design and sample collection*

413 The PITCH consortium has been described previously (Angyal et al., 2022; Moore et
414 al., 2022; Payne et al., 2021). Briefly, participants in this prospective, observational,
415 cohort study were recruited from five university hospitals in England (Birmingham,
416 Liverpool, Newcastle, Oxford and Sheffield). Recruitment of consenting individuals
417 was by word of mouth, hospital e-mail communications and from hospital-based staff
418 screening programmes for SARS-CoV-2, including HCWs enrolled in the national
419 SIREN study at three sites (Liverpool, Newcastle and Sheffield). Eligible participants
420 were adults aged 18 or over, and currently working as HCWs, including allied
421 support and laboratory staff, or were volunteers linked to the hospital. Individuals
422 were defined as SARS-CoV-2 naive or previously-infected based on documented
423 PCR and/or serology results from local NHS trusts, or the Meso Scale Discovery
424 (MSD) assay S and N antibody results if these data were not available locally, as
425 described previously (Payne et al., 2021).

426 PITCH is a sub-study of the SIREN study, which was approved by the Berkshire
427 Research Ethics Committee, Health Research 250 Authority (IRAS ID 284460, REC
428 reference 20/SC/0230), with PITCH recognised as a sub-study on 2 December 2020.
429 SIREN is registered with ISRCTN (Trial ID: 252 ISRCTN11041050). Some
430 participants were recruited under aligned study protocols. In Birmingham participants
431 were recruited under the “Determining the immune response to SARS-CoV-2
432 infection in convalescent health care workers” (COCO) study (IRAS ID: 282525). In
433 Liverpool some participants were recruited under the “Human immune responses to
434 acute virus infections” Study (16/NW/0170), approved by North West - Liverpool
435 Central Research Ethics Committee on 8 March 2016, and amended on 14th
436 September 2020 and 4th May 2021. In Oxford, participants were recruited under the
437 GI Biobank Study 16/YH/0247, approved by the research ethics committee (REC) at
438 Yorkshire & The Humber - Sheffield Research Ethics Committee on 29 July 2016,
439 which has been amended for this purpose on 8 June 2020. In Sheffield, participants
440 were recruited under the Observational Biobanking study STHObs (18/YH/0441),
441 which was amended for this study on 10 September 2020. The study was conducted
442 in compliance with all relevant ethical regulations for work with human participants,
443 and according to the principles of the Declaration of Helsinki (2008) and the
444 International Conference on Harmonization (ICH) Good Clinical Practice (GCP)
445 guidelines. Written informed consent was obtained for all participants enrolled in the
446 study.

447 The current study is nested within PITCH. A vaccine breakthrough case was defined
448 as a self-reported positive PCR or LFD test for SARS-CoV-2 >14 days after second
449 vaccine dose and <7 days after the third vaccine dose. The period of interest for

450 cases was when Delta was the predominant circulating SARS-CoV-2 variant in the
451 UK, defined here as 6th June to 27th November 2021, with 27th November taken as
452 the cut-off date as this was the date of the first reported cases of SARS-CoV-2
453 Omicron variant in the UK (Department of Health and Social Care, 2021).
454 Throughout this period $\geq 89.9\%$ of genotyped infections across England were
455 attributable to the Delta variant (UK Health Security Agency, 2021). During this
456 period all UK HCWs were requested to undertake twice-weekly asymptomatic testing
457 for SARS-CoV-2 using self-swab LFDs which were provided free of charge by
458 workplaces, pharmacies and by postal delivery from the government website.
459 Symptomatic PCR testing was readily available at this time free of charge from
460 hospital trusts and UK community testing programmes. Adherence to this testing
461 was not measured within PITCH, however, PITCH participants are asked about
462 SARS-CoV-2 infections at every clinic visit.

463 The current study has a case-control design (Supplementary Figure S1). Eligibility
464 criteria were enrolment in PITCH by 30th June 2021, and being double vaccinated by
465 31st July 2021. For correlates analysis, all those meeting the criteria of a vaccine
466 breakthrough case and who had been sampled at the V2+28 timepoint were
467 included. Controls were those who had been sampled at the V2+28 timepoint and
468 did not report a positive PCR or LFD by 27th November 2021 or 7 days after the third
469 vaccine dose (V3+7), whichever was earlier, and who did not show detectable N
470 seroconversion (defined as anti-N IgG titre over the positivity threshold previously
471 defined using pre-pandemic samples (Angyal et al., 2022), and at least double the
472 individual's baseline value) in available follow-up data during this time
473 (Supplementary Table S1, S2).

474 A subset of cases was selected on the basis of sample availability for further
475 analysis using ICS and memory B cell FluoroSpot. Controls were matched with these
476 cases for each assay, with matching based on age, sex, previous infection status at
477 enrolment, vaccine manufacturer and dose interval (Supplementary Table S3).
478 Cases in this matched analysis had been enrolled at multiple sites, whereas controls
479 had all been enrolled at the Oxford site. All experiments for this subset analysis were
480 conducted at the Oxford site.

481 Participants were sampled for the current study between 4th January 2021 and 13th
482 August 2021, approximately 28 days after their second vaccine dose (median 28
483 days, IQR 26-33 days). PBMC, plasma and serum were separated and
484 cryopreserved. The majority of participants had been investigated for previous
485 reports of the PITCH cohort (Angyal et al., 2022; Moore et al., 2022; Payne et al.,
486 2021; Skelly et al., 2021).

487 *Demographic analysis*

488 Demographic characteristics of vaccine breakthrough cases compared to the PITCH
489 cohort were initially analysed by univariable logistic regression to estimate the crude
490 odds ratio for vaccine breakthrough for each variable. A likelihood ratio test was
491 conducted with the null hypothesis of no association between vaccine breakthrough
492 and each variable. An adjusted model was derived by backwards stepwise
493 regression, with age and sex included as *a priori* confounders. Variables were
494 removed from the model sequentially, beginning with those with the least effect in
495 univariable regression. A likelihood ratio test was conducted after each removal, and
496 only those variables with evidence of association with vaccine breakthrough ($p < 0.05$)
497 were retained in the model. Analysis was performed using R version 4.1.2 (The R
498 Foundation for Statistical Computing, Vienna, Austria, 2021. URL [https://www.R-](https://www.R-project.org/)
499 [project.org/](https://www.R-project.org/)). Confidence intervals were derived using the `confint` package.

500 *T cell IFN γ ELISpot assay*

501 IFN γ ELISpot assays were performed using the Human IFN γ ELISpot Basic kit
502 (Mabtech 3420-2A), according to the PITCH ELISpot Standard Operating Procedure
503 as previously published (Angyal et al., 2022). Cryopreserved PBMC were thawed in
504 R10 media (RPMI 1640 with 10% (v/v) Fetal Bovine Serum, 2mM L-Glutamine and
505 1mM Penicillin/Streptomycin (all Sigma)) and rested for 3-6 hours in a humidified
506 incubator at 37°C, 5% CO₂. MultiScreen-IP filter plates (Millipore) were coated with
507 10 μ g/ml capture antibody (clone 1-D1K, Mabtech) for 3-8 hours and blocked with
508 R10 or Rab10 (RPMI 1640 with 2mM L-Glutamine and 1mM Penicillin/Streptomycin
509 supplemented with 10% (v/v) Human AB Serum (Sigma)) for 1-8 hours at room
510 temperature (RT). PBMC were resuspended in R10 or Rab10, plated in triplicate at
511 2×10^5 cells/well and stimulated as follows. PBMC were stimulated with overlapping
512 peptide pools (18-mers with 10 amino acid overlap, Mimotopes) spanning the S or
513 membrane (M) and N SARS-CoV-2 proteins at a final concentration of 2 μ g/ml for 16-
514 18 hours in a humidified incubator at 37°C, 5% CO₂. For selected individuals, pools
515 spanning S protein of the Delta variant were included. Pools consisting of CMV, EBV
516 and influenza peptides at a final concentration of 2 μ g/ml (CEF; Proimmune) and
517 concanavalin A or phytohemagglutinin L (PHA-L, Sigma) were used as positive
518 controls. DMSO was used as the negative control at an equivalent concentration to
519 the peptides. After the incubation period and all subsequent steps plates were
520 washed with PBS supplemented with 0.05% (v/v) Tween20 (Sigma). Detection
521 antibody (clone 7-B6-1, Mabtech) was added and incubated for 2-4 hours at RT.
522 Plates were washed and streptavidin-ALP (Mabtech) added for 1-2 hours at RT,
523 before washing again and addition of 1-step NBT/BCIP substrate solution (Thermo
524 Scientific) for 5-7 minutes at RT. Colour development was stopped by washing with
525 tap water. Air-dried plates were scanned and analysed with the AID Classic ELISpot
526 reader (software version 8.0, Autoimmune Diagnostika GmbH, Germany) or
527 ImmunoSpot® S6 Alfa Analyser (Cellular Technology Limited LLC, Germany).
528 Antigen-specific responses were calculated by subtracting the mean number of spots

529 in the DMSO wells from the test wells and expressed as spot-forming units
530 (SFU)/10⁶ PBMC. Samples with a mean spot value >50 in the DMSO wells were
531 excluded from analysis.

532 *MSD IgG binding assay*

533 IgG responses to SARS-CoV-2, SARS-CoV-1, MERS-CoV and seasonal
534 coronaviruses were measured using a multiplexed MSD immunoassay (The V-PLEX
535 COVID-19 Coronavirus Panel 3 (IgG) Kit (cat. no. K15399U) from Meso Scale
536 Discovery, Rockville, MD USA), as reported previously (Moore et al., 2022; Payne et
537 al., 2021). A MULTI-SPOT® 96-well, 10 spot plate was coated with three SARS
538 CoV-2 antigens (S, RBD, N), SARS-CoV-1 and MERS-CoV spike trimers, spike
539 proteins from seasonal human coronaviruses, HCoV-OC43, HCoV-HKU1, HCoV-
540 229E and HCoV-NL63, and bovine serum albumin (negative control). Antigens were
541 spotted at 200–400 µg/mL (MSD® Coronavirus Plate 3). Multiplex MSD assays were
542 performed as per the manufacturer's instructions. To measure IgG antibodies, 96-
543 well plates were blocked with MSD Blocker A for 30 minutes. Following washing with
544 washing buffer, serum or plasma samples diluted 1:1,000-30,000 in diluent buffer,
545 MSD standard and undiluted internal MSD controls, were added to the wells. After 2-
546 hour incubation and washing, detection antibody (MSD SULFO-TAG™ anti-human
547 IgG antibody, 1/200) was added. Following washing, MSD GOLD™ read buffer B
548 was added and plates were read using a MESO® SECTOR S 600 reader. The
549 standard curve was established by fitting the signals from the reference standard
550 using a 4-parameter logistic model. Concentrations of samples were determined
551 from the electrochemiluminescence signals by back-fitting to the standard curve and
552 multiplying by the dilution factor. Concentrations are expressed in Arbitrary Units/ml
553 (AU/ml). Thresholds were previously determined for each SARS-CoV-2 antigen
554 based on the mean concentrations measured in 103 pre-pandemic sera + 3
555 Standard Deviations (Angyal et al., 2022). Thresholds were: S, 1160 AU/ml; RBD,
556 1169 AU/ml; and N, 3874 AU/ml.

557 *Memory B cell IgG FluoroSpot assay*

558 In a subset of cases and matched controls for which PBMC were available, B cell
559 memory responses were characterised by IgG FluoroSpot assay, according to
560 methods previously reported (Moore et al., 2022). Cryopreserved PBMC were
561 thawed and rested for 4-6 hours in R10 media, then cultured in R10 supplemented
562 with 2mM Sodium Pyruvate, 2mM MEM Non-Essential Amino Acids, 200nM 2-
563 Mercaptoethanol (all Life Technologies), 1µg/ml R848 and 10ng/ml IL-2 (Mabtech
564 Human memory B cell stimpack) for 68-72 hours in a humidified incubator at 37°C,
565 5% CO₂, for polyclonal stimulation. Using the Human IgA/IgG FluoroSpotFLEX kit
566 (Mabtech), stimulated PBMC were then added at 2x10⁵ cells/well to FluoroSpot
567 plates coated with 10µg/ml ancestral and Delta SARS-CoV-2 S glycoprotein, PBS

568 (negative control) or capture mAbs (positive control). Plates were incubated for 18
569 hours in a humidified incubator at 37°C, 5% CO₂ and developed according to the
570 manufacturer's instructions (Mabtech). Analysis was carried out with AID ELISpot
571 software 8.0 (Autoimmun Diagnostika). Samples were tested in duplicate, or
572 triplicate where cell counts permitted. Antigen-specific responses were calculated by
573 subtracting the mean number of spots in the PBS wells from the test wells and
574 expressed as antibody-secreting cells (ASC)/10⁶ PBMC.

575 *Intracellular cytokine staining assay*

576 In a subset of cases and matched controls for which PBMC were available, T cell
577 responses were characterised further using ICS after stimulation with overlapping
578 SARS-CoV-2 peptide pools, according to methods reported previously (Moore et al.,
579 2022). Cryopreserved PBMC were thawed and rested in R10 media for 4-6 hours,
580 then plated at 1x10⁶ cells/well in a 96-well U-bottom plate together with co-
581 stimulatory molecules anti-CD28 and anti-CD49d (both BD) at 1µg/ml final
582 concentration. Peptide pools spanning ancestral and Delta S proteins were added at
583 2µg/ml final concentration for each peptide pool. DMSO (Sigma) was used as the
584 negative control at the equivalent concentration to the peptides. As a positive control,
585 cells were stimulated with 1x cell activation cocktail containing phorbol-12-myristate
586 13-acetate (PMA) at 81µM and ionomycin at 1.3µM final concentration (Biolegend).
587 Cells were then incubated in a humidified incubator at 37°C, 5% CO₂ for 1 hour
588 before incubating for a further 15 hours in the presence of 5µg/ml Brefeldin A
589 (Biolegend). Flow cytometry staining was then performed as follows. Cell staining
590 buffer (Biolegend) was used for staining and washing before fixation, with 1x
591 Perm/Wash buffer (BD) used after fixation. At the end of the culture period, PBMC
592 were washed once and subsequently stained with near-infrared fixable live/dead
593 stain (Invitrogen), fluorochrome-conjugated primary human-specific antibodies
594 against CD4, CD8 and CD14 (all Biolegend) and human Fc blocking reagent
595 (Miltenyi Biotec) for 20 minutes at 4°C in the dark. PBMC were washed and then
596 fixed and permeabilised in Cytotfix/Cytoperm buffer (BD) for 20 minutes at 4°C in the
597 dark. PBMC were then washed followed by staining with primary human-specific
598 antibodies against CD3, IFN γ , TNF (all Biolegend), IL-2 (eBioscience) and human Fc
599 blocking reagent for 20 minutes at 4°C in the dark. PBMC were washed,
600 resuspended in cell staining buffer, and stored at 4°C for up to 6 hours until
601 acquisition. Samples were acquired on a MACSQuant analyser 10 and X (Miltenyi
602 Biotec) and analysis was performed using FlowJo software version 10.8.1 (BD
603 Biosciences). Example gating strategy is shown in Supplementary Figure S4. Details
604 of antibodies used are listed in Supplementary Table S4.

605 *High-throughput live virus microneutralisation assay*

606 In a subset of cases and controls, high-throughput live virus microneutralisation
607 assays were performed as described previously (Faulkner et al., 2021; Wall et al.,
608 2021). Briefly, Vero E6 cells (Institute Pasteur) (Rihn et al., 2021) at 90-100%
609 confluency in 384-well format were first titrated with varying MOIs of each SARS-
610 CoV-2 variant and varying concentrations of a control monoclonal nanobody in order
611 to normalise for possible replicative differences between variants and select
612 conditions equivalent to wild-type virus. Following this calibration, cells were infected
613 in the presence of serial dilutions of patient serum samples. 24 hrs after infection,
614 cells were fixed with 4% final Formaldehyde, permeabilised with 0.2% TritonX-100,
615 3% BSA in PBS (v/v), and stained for SARS-CoV-2 N protein using Biotin-labelled-
616 CR3009 antibody produced in-house in conjunction with Alexa488-Streptavidin
617 (Invitrogen S32354) and cellular DNA using DAPI (van den Brink et al., 2005).
618 Whole-well imaging at 5x was carried out using an Opera Phenix (Perkin Elmer) and
619 fluorescent areas and intensity calculated using the Phenix-associated software
620 Harmony (Perkin Elmer). Inhibition was estimated from the measured area of
621 infected cells/total area occupied by all cells. The inhibitory profile of each serum
622 sample was estimated by fitting a 4-parameter dose response curve executed in
623 SciPy. Neutralising antibody titres are reported as the fold-dilution of serum required
624 to inhibit 50% of viral replication (IC₅₀), and are further annotated if they lie above
625 the quantitative (complete inhibition) range (titre >2560), below the quantitative range
626 (<40) but still within the qualitative range (i.e. partial inhibition is observed but a
627 dose-response curve cannot be fit because it does not sufficiently span the IC₅₀), or
628 if they show no inhibition at all. For plotting, complete, weak and no inhibition were
629 assigned 5120, 10 and 5 respectively. Details of viruses used in the study are listed
630 in Supplementary Table S5.

631 *Statistical analysis*

632 Continuous variables are displayed as median and interquartile range (IQR).
633 Unpaired comparisons between two groups were analysed using the Mann-Whitney
634 U test. Paired comparisons between two groups were analysed by the Wilcoxon
635 matched-pairs signed-rank test. Comparison between four groups was carried out
636 using Fisher's exact test and post-hoc paired Fisher's exact tests adjusted with the
637 Bonferroni correction. P values are two-tailed. Statistical analyses were performed
638 using R version 4.1.2 (The R Foundation for Statistical Computing, Vienna, Austria,
639 2021. URL <https://www.R-project.org/>) and GraphPad Prism 9.4.0.

640 **ACKNOWLEDGEMENTS**

641 We are grateful to all the volunteers who participated in the PITCH study. For the
642 Birmingham participants, the study was carried out at the National Institute for Health
643 Research (NIHR)/Wellcome Trust Birmingham Clinical Research Facility. Laboratory
644 studies were undertaken by the Clinical Immunology Service, University of
645 Birmingham. We thank Prof. Wendy Barclay of Imperial College and the wider
646 Genotype to Phenotype consortium for the Delta strain used for the live virus
647 microneutralisation assay in this study.

648 **AUTHOR CONTRIBUTIONS**

649 Conceptualization, S.J.D, P.K, T.L, A.R, C.J.A.D, L.T, T.I.d.S, M.C, S.H, V.H;
650 Methodology, S.J.D, P.K, T.L, B.K, S.L, E.J.C, R.B, A.R, C.J.A.D, L.T, T.I.d.S, M.C;
651 Formal analysis, I.N, M.A; Investigation, I.N, M.A, S.L, P.A, M.Y.W, E.J.C, L.S, S.D,
652 M.P, T.A.H.N, R.P.P, E.B, C.J.A.D, A.R, R.B; Resources, A.B, A.D.O; Data Curation,
653 S.C.M, A.S.D; Writing – Original Draft, I.N; Writing – Review & Editing, S.J.D, P.K,
654 T.L, T.I.d.S, L.T., E.J.C, S.L, M.A; Visualization, I.N; Supervision, S.J.D, P.K, T.L,
655 B.K, M.C, T.I.d.S, L.T, A.T; Project Administration, A.S.D; Funding Acquisition, P.K.,
656 S.J.D., L.T., T.I.d.S, C.J.A.D., A.R., S.H., V.H.

657 **FUNDING STATEMENT**

658 This research was funded in part by the Wellcome Trust (WT109965MA,
659 110058/Z/15/Z, 204721/Z/16/Z, 211153/Z/18/Z, 205228/Z/16/Z, 090532/Z/09/Z,
660 CC2230, CC2087). This work was funded by the United Kingdom Department of
661 Health and Social Care as part of the PITCH (Protective Immunity from T cells to
662 COVID-19 in Healthcare Workers) Consortium, UKRI as part of “Investigation of
663 proven vaccine breakthrough by SARS-CoV-2 variants in established UK healthcare
664 worker cohorts: SIREN consortium & PITCH Plus Pathway” (MR/W02067X/1), with
665 contributions from UKRI/NIHR through the UK Coronavirus Immunology Consortium
666 (UK-CIC), the Huo Family Foundation and The National Institute for Health Research
667 (UKRIDHSC COVID-19 Rapid Response Rolling Call, Grant Reference Number
668 COV19-RECPLAS). This work was supported by the Francis Crick Institute which
669 receives its core funding from Cancer Research UK (CC2230, CC2087), the UK
670 Medical Research Council (CC2230, CC2087), and the Wellcome Trust (CC2230,
671 CC2087).

672 S.D. is funded by an NIHR Global Research Professorship (NIHR300791). E.B. and
673 P.K. are NIHR Senior Investigators and P.K. is funded by WT109965MA. T.I.d.S is
674 funded by a Wellcome Trust Intermediate Clinical Fellowship (110058/Z/15/Z).
675 R.P.P. is funded by a Career Re-entry Fellowship (204721/Z/16/Z). C.J.A.D. is

676 funded by a Wellcome Clinical Research Career Development Fellowship
677 (211153/Z/18/Z). L.T. is supported by the Wellcome Trust (205228/Z/16/Z), the
678 National Institute for Health Research Health Protection Research Unit (NIHR
679 HPRU) in Emerging and Zoonotic Infections (EZI) (NIHR200907) and the Centre of
680 Excellence in Infectious Diseases Research (CEIDR) and the Alder Hey Charity. The
681 HPRU-EZI at University of Liverpool is in partnership with UK Health Security
682 Agency, in collaboration with Liverpool School of Tropical Medicine and the
683 University of Oxford. M.C., S.L., and L.T. are supported by US Food and Drug
684 Administration Medical Countermeasures Initiative contract 75F40120C00085. The
685 Wellcome Centre for Human Genetics is supported by the Wellcome Trust
686 (090532/Z/09/Z). The Sheffield Teaching Hospitals Observational Study of Patients
687 with Pulmonary Hypertension, Cardiovascular and other Respiratory Diseases (STH-
688 ObS) was supported by the British Heart Foundation (PG/11/116/29288). The STH-
689 ObS Chief Investigator Allan Lawrie is supported by a British Heart Foundation
690 Senior Basic Science Research Fellowship (FS/18/52/33808). We gratefully
691 acknowledge financial support from the UK Department of Health via the Sheffield
692 NIHR Clinical Research Facility award to the Sheffield Teaching Hospitals
693 Foundation NHS Trust.

694 The views expressed are those of the author(s) and not necessarily those of the
695 NHS, the NIHR, the Department of Health and Social Care or UK Health Security
696 Agency, or the US Food and Drug Administration.

697 **COMPETING INTEREST STATEMENT**

698 S.D. is a Scientific Advisor to the Scottish Parliament on COVID-19 for which she
699 receives a fee. Oxford University has entered a joint COVID-19 vaccine development
700 partnership with AstraZeneca. All other authors have declared no competing
701 interests.

702 REFERENCES

- 703 Addetia, A., Crawford, K.H.D., Dingens, A., Zhu, H., Roychoudhury, P., Huang, M.L.,
704 Jerome, K.R., Bloom, J.D., and Greninger, A.L. (2020). Neutralizing Antibodies Correlate
705 with Protection from SARS-CoV-2 in Humans during a Fishery Vessel Outbreak with a High
706 Attack Rate. *Journal of Clinical Microbiology* 58. 10.1128/jcm.02107-20.
- 707 Aldridge, R.W., Yavlinsky, A., Nguyen, V., Eyre, M.T., Shrotri, M., Navaratnam, A.M.D.,
708 Beale, S., Braithwaite, I., Byrne, T., Kovar, J., et al. (2022). SARS-CoV-2 antibodies and
709 breakthrough infections in the Virus Watch cohort. *Nature Communications* 13.
710 10.1038/s41467-022-32265-5.
- 711 Almendro-Vázquez, P., Chivite-Lacaba, M., Utrero-Rico, A., González-Cuadrado, C.,
712 Laguna-Goya, R., Moreno-Batanero, M., Sánchez-Paz, L., Luczkowiak, J., Labiod, N.,
713 Folgueira, M.D., et al. (2022). Cellular and humoral immune responses and breakthrough
714 infections after three SARS-CoV-2 mRNA vaccine doses. *Frontiers in Immunology* 13,
715 981350-981350. 10.3389/fimmu.2022.981350.
- 716 Angyal, A., Longet, S., Moore, S., Payne, R.P., Harding, A., Tipton, T., Rongkard, P., Ali, M.,
717 Hering, L.M., Meardon, N., et al. (2022). T-cell and antibody responses to first BNT162b2
718 vaccine dose in previously infected and SARS-CoV-2-naive UK health-care workers: a
719 multicentre prospective cohort study. *The Lancet Microbe* 3, e21-e31. 10.1016/s2666-
720 5247(21)00275-5.
- 721 Atti, A., Insalata, F., Carr, E.J., Otter, A.D., Castillo-Olivares, J., Wu, M., Harvey, R., Howell,
722 M., Chan, A., Lyall, J., et al. (2022). Antibody correlates of protection from SARS-CoV-2
723 reinfection prior to vaccination: A nested case-control within the SIREN study. *Journal of*
724 *Infection* 85, 545-556. 10.1016/j.jinf.2022.09.004.
- 725 Bergwerk, M., Gonen, T., Lustig, Y., Amit, S., Lipsitch, M., Cohen, C., Mandelboim, M.,
726 Levin, E.G., Rubin, C., Indenbaum, V., et al. (2021). Covid-19 Breakthrough Infections in
727 Vaccinated Health Care Workers. *New England Journal of Medicine* 385, 1474-1484.
728 10.1056/nejmoa2109072.
- 729 Brasu, N., Elia, I., Russo, V., Montacchiesi, G., Stabile, S.A., De Intinis, C., Fesi, F., Gizzi,
730 K., Macagno, M., Montone, M., et al. (2022). Memory CD8+ T cell diversity and B cell
731 responses correlate with protection against SARS-CoV-2 following mRNA vaccination.
732 *Nature Immunology* 23, 1445-1456. 10.1038/s41590-022-01313-z.
- 733 Cele, S., Jackson, L., Khoury, D.S., Khan, K., Moyo-Gwete, T., Tegally, H., San, J.E.,
734 Cromer, D., Scheepers, C., Amoako, D.G., et al. (2022). Omicron extensively but
735 incompletely escapes Pfizer BNT162b2 neutralization. *Nature* 602, 654-656.
736 10.1038/s41586-021-04387-1.
- 737 Chau, N.V.V., Ngoc, N.M., Nguyet, L.A., Quang, V.M., Ny, N.T.H., Khoa, D.B., Phong, N.T.,
738 Toan, L.M., Hong, N.T.T., Tuyen, N.T.K., et al. (2021). An observational study of
739 breakthrough SARS-CoV-2 Delta variant infections among vaccinated healthcare workers in
740 Vietnam. *eClinicalMedicine* 41, 101143. 10.1016/j.eclinm.2021.101143.
- 741 Collie, S., Champion, J., Moultrie, H., Bekker, L.-G., and Gray, G. (2022). Effectiveness of
742 BNT162b2 Vaccine against Omicron Variant in South Africa. *New England Journal of*
743 *Medicine* 386, 494-496. 10.1056/nejmc2119270.

- 744 Department of Health and Social Care (2021). Press Release: First UK cases of Omicron
745 variant identified. [https://www.gov.uk/government/news/first-uk-cases-of-omicron-variant-](https://www.gov.uk/government/news/first-uk-cases-of-omicron-variant-identified)
746 [identified](https://www.gov.uk/government/news/first-uk-cases-of-omicron-variant-identified).
- 747 Dhumal, S., Patil, A., More, A., Kamtalwar, S., Joshi, A., Gokarn, A., Mirgh, S., Thatikonda,
748 P., Bhat, P., Murthy, V., et al. (2022). SARS-CoV-2 reinfection after previous infection and
749 vaccine breakthrough infection through the second wave of pandemic in India: An
750 observational study. *International Journal of Infectious Diseases* 118, 95-103.
751 10.1016/j.ijid.2022.02.037.
- 752 Earle, K.A., Ambrosino, D.M., Fiore-Gartland, A., Goldblatt, D., Gilbert, P.B., Siber, G.R.,
753 Dull, P., and Plotkin, S.A. (2021). Evidence for antibody as a protective correlate for COVID-
754 19 vaccines. *Vaccine* 39, 4423-4428. 10.1016/j.vaccine.2021.05.063.
- 755 Faulkner, N., Ng, K.W., Wu, M.Y., Harvey, R., Margaritis, M., Paraskevopoulou, S.,
756 Houlihan, C., Hussain, S., Greco, M., Bolland, W., et al. (2021). Reduced antibody cross-
757 reactivity following infection with B.1.1.7 than with parental SARS-CoV-2 strains. *eLife* 10.
758 10.7554/elife.69317.
- 759 Feng, S., Phillips, D.J., White, T., Sayal, H., Aley, P.K., Bibi, S., Dold, C., Fuskova, M.,
760 Gilbert, S.C., Hirsch, I., et al. (2021). Correlates of protection against symptomatic and
761 asymptomatic SARS-CoV-2 infection. *Nature Medicine* 27, 2032-2040. 10.1038/s41591-021-
762 01540-1.
- 763 Follmann, D., Janes, H.E., Buhule, O.D., Zhou, H., Girard, B., Marks, K., Kotloff, K.,
764 Desjardins, M., Corey, L., Neuzil, K.M., et al. (2022). Antinucleocapsid Antibodies After
765 SARS-CoV-2 Infection in the Blinded Phase of the Randomized, Placebo-Controlled mRNA-
766 1273 COVID-19 Vaccine Efficacy Clinical Trial. *Ann Intern Med* 175, 1258-1265.
767 10.7326/M22-1300.
- 768 Gao, Y., Cai, C., Grifoni, A., Müller, T.R., Niessl, J., Olofsson, A., Humbert, M., Hansson, L.,
769 Österborg, A., Bergman, P., et al. (2022). Ancestral SARS-CoV-2-specific T cells cross-
770 recognize the Omicron variant. *Nature Medicine* 28, 472-476. 10.1038/s41591-022-01700-x.
- 771 Gilbert, P.B., Montefiori, D.C., McDermott, A.B., Fong, Y., Benkeser, D., Deng, W., Zhou, H.,
772 Houchens, C.R., Martins, K., Jayashankar, L., et al. (2022). Immune correlates analysis of
773 the mRNA-1273 COVID-19 vaccine efficacy clinical trial. *Science* 375, 43-50.
774 10.1126/science.abm3425.
- 775 Green, A., Curtis, H., Hulme, W., Williamson, E., McDonald, H., Bhaskaran, K., Rentsch, C.,
776 Schultze, A., Mackenna, B., Mahalingasivam, V., et al. (2022). Describing the population
777 experiencing COVID-19 vaccine breakthrough following second vaccination in England: a
778 cohort study from OpenSAFELY. *BMC Medicine* 20. 10.1186/s12916-022-02422-0.
- 779 Hall, V., Foulkes, S., Insalata, F., Kirwan, P., Saei, A., Atti, A., Wellington, E., Khawam, J.,
780 Munro, K., Cole, M., et al. (2022). Protection against SARS-CoV-2 after Covid-19
781 Vaccination and Previous Infection. *New England Journal of Medicine* 386, 1207-1220.
782 10.1056/nejmoa2118691.
- 783 Hall, V.J., Foulkes, S., Charlett, A., Atti, A., Monk, E.J.M., Simmons, R., Wellington, E., Cole,
784 M.J., Saei, A., Oguti, B., et al. (2021a). SARS-CoV-2 infection rates of antibody-positive
785 compared with antibody-negative health-care workers in England: a large, multicentre,
786 prospective cohort study (SIREN). *The Lancet* 397, 1459-1469. 10.1016/s0140-
787 6736(21)00675-9.

- 788 Hall, V.J., Foulkes, S., Saei, A., Andrews, N., Oguti, B., Charlett, A., Wellington, E., Stowe,
789 J., Gillson, N., Atti, A., et al. (2021b). COVID-19 vaccine coverage in health-care workers in
790 England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a
791 prospective, multicentre, cohort study. *The Lancet* 397, 1725-1735. 10.1016/s0140-
792 6736(21)00790-x.
- 793 Kedzierska, K., and Thomas, P.G. (2022). Count on us: T cells in SARS-CoV-2 infection and
794 vaccination. *Cell Reports Medicine* 3, 100562. 10.1016/j.xcrm.2022.100562.
- 795 Kent, S.J., Khoury, D.S., Reynaldi, A., Juno, J.A., Wheatley, A.K., Stadler, E., John Wherry,
796 E., Triccas, J., Sasson, S.C., Cromer, D., and Davenport, M.P. (2022). Disentangling the
797 relative importance of T cell responses in COVID-19: leading actors or supporting cast?
798 *Nature Reviews Immunology* 22, 387-397. 10.1038/s41577-022-00716-1.
- 799 Khoury, D.S., Cromer, D., Reynaldi, A., Schlub, T.E., Wheatley, A.K., Juno, J.A., Subbarao,
800 K., Kent, S.J., Triccas, J.A., and Davenport, M.P. (2021). Neutralizing antibody levels are
801 highly predictive of immune protection from symptomatic SARS-CoV-2 infection. *Nature*
802 *Medicine* 27, 1205-1211. 10.1038/s41591-021-01377-8.
- 803 Kundu, R., Narean, J.S., Wang, L., Fenn, J., Pillay, T., Fernandez, N.D., Conibear, E.,
804 Koycheva, A., Davies, M., Tolosa-Wright, M., et al. (2022). Cross-reactive memory T cells
805 associate with protection against SARS-CoV-2 infection in COVID-19 contacts. *Nature*
806 *Communications* 13. 10.1038/s41467-021-27674-x.
- 807 Levin, E.G., Lustig, Y., Cohen, C., Fluss, R., Indenbaum, V., Amit, S., Doolman, R., Asraf,
808 K., Mendelson, E., Ziv, A., et al. (2021). Waning Immune Humoral Response to BNT162b2
809 Covid-19 Vaccine over 6 Months. *New England Journal of Medicine* 385, e84.
810 10.1056/nejmoa2114583.
- 811 Lim, J.M.E., Tan, A.T., Le Bert, N., Hang, S.K., Low, J.G.H., and Bertoletti, A. (2022). SARS-
812 CoV-2 breakthrough infection in vaccinees induces virus-specific nasal-resident CD8+ and
813 CD4+ T cells of broad specificity. *Journal of Experimental Medicine* 219.
814 10.1084/jem.20220780.
- 815 Liu, J., Yu, J., McMahan, K., Jacob-Dolan, C., He, X., Giffin, V., Wu, C., Sciacca, M.,
816 Powers, O., Nampanya, F., et al. (2022). CD8 T Cells Contribute to Vaccine Protection
817 Against SARS-CoV-2 in Macaques. *Science Immunology*, eabq7647.
818 10.1126/sciimmunol.abq7647.
- 819 McMahan, K., Yu, J., Mercado, N.B., Loos, C., Tostanoski, L.H., Chandrashekar, A., Liu, J.,
820 Peter, L., Atyeo, C., Zhu, A., et al. (2021). Correlates of protection against SARS-CoV-2 in
821 rhesus macaques. *Nature* 590, 630-634. 10.1038/s41586-020-03041-6.
- 822 Mentzer, A.J., O'Connor, D., Bibi, S., Chelysheva, I., Clutterbuck, E.A., Demissie, T., Dinesh,
823 T., Edwards, N.J., Felle, S., Feng, S., et al. (2022). Human leukocyte antigen alleles
824 associate with COVID-19 vaccine immunogenicity and risk of breakthrough infection. *Nature*
825 *Medicine*. 10.1038/s41591-022-02078-6.
- 826 Mohlendick, B., Ciuciulkaite, I., Elsner, C., Anastasiou, O.E., Trilling, M., Wagner, B.,
827 Zwanziger, D., Jockel, K.H., Dittmer, U., and Siffert, W. (2022). Individuals With Weaker
828 Antibody Responses After Booster Immunization Are Prone to Omicron Breakthrough
829 Infections. *Frontiers in Immunology* 13, 907343. 10.3389/fimmu.2022.907343.
- 830 Molodtsov, I.A., Kegeles, E., Mitin, A.N., Mityaeva, O., Musatova, O.E., Panova, A.E.,
831 Pashenkov, M.V., Peshkova, I.O., Alsalloum, A., Asaad, W., et al. (2022). Severe Acute

- 832 Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)-Specific T Cells and Antibodies in
833 Coronavirus Disease 2019 (COVID-19) Protection: A Prospective Study. *Clinical Infectious*
834 *Diseases* 75, e1-e9. 10.1093/cid/ciac278.
- 835 Moore, S.C., Kronsteiner, B., Longet, S., Adele, S., Deeks, A.S., Liu, C., Dejnirattisai, W.,
836 Silva Reyes, L., Meardon, N., Faustini, S., et al. (2022). Evolution of long-term hybrid
837 immunity in healthcare workers after different COVID-19 vaccination regimens: a longitudinal
838 observational cohort study. *MedRxiv*. 10.1101/2022.06.06.22275865.
- 839 Moss, P. (2022). The T cell immune response against SARS-CoV-2. *Nature Immunology* 23,
840 186-193. 10.1038/s41590-021-01122-w.
- 841 Naaber, P., Tserel, L., Kangro, K., Sepp, E., Jurjenson, V., Adamson, A., Haljasmagi, L.,
842 Rumm, A.P., Maruste, R., Karner, J., et al. (2021). Dynamics of antibody response to
843 BNT162b2 vaccine after six months: a longitudinal prospective study. *Lancet Regional*
844 *Health Europe* 10, 100208. 10.1016/j.lanepe.2021.100208.
- 845 Nunes, M.C., Mbotwe-Sibanda, S., Baillie, V.L., Kwatra, G., Aguas, R., and Madhi, S.A.
846 (2022). SARS-CoV-2 Omicron Symptomatic Infections in Previously Infected or Vaccinated
847 South African Healthcare Workers. *Vaccines* 10, 459. 10.3390/vaccines10030459.
- 848 Ogbe, A., Kronsteiner, B., Skelly, D.T., Pace, M., Brown, A., Adland, E., Adair, K., Akhter,
849 H.D., Ali, M., Ali, S.-E., et al. (2021). T cell assays differentiate clinical and subclinical SARS-
850 CoV-2 infections from cross-reactive antiviral responses. *Nature Communications* 12.
851 10.1038/s41467-021-21856-3.
- 852 Park, H.-S., Shapiro, J.R., Sitaras, I., Woldemeskel, B.A., Garliss, C.C., Dziedzic, A.,
853 Sachithanandham, J., Jedlicka, A.E., Caputo, C.A., Rousseau, K.E., et al. (2022). Adaptive
854 immune responses in vaccinated patients with symptomatic SARS-CoV-2 Alpha infection.
855 *JCI Insight* 7. 10.1172/jci.insight.155944.
- 856 Parry, H., Bruton, R., Stephens, C., Bentley, C., Brown, K., Amirthalingam, G., Hallis, B.,
857 Otter, A., Zuo, J., and Moss, P. (2022). Extended interval BNT162b2 vaccination enhances
858 peak antibody generation. *npj Vaccines* 7. 10.1038/s41541-022-00432-w.
- 859 Payne, R.P., Longet, S., Austin, J.A., Skelly, D.T., Dejnirattisai, W., Adele, S., Meardon, N.,
860 Faustini, S., Al-Taei, S., Moore, S.C., et al. (2021). Immunogenicity of standard and
861 extended dosing intervals of BNT162b2 mRNA vaccine. *Cell* 184, 5699-5714.e5611.
862 10.1016/j.cell.2021.10.011.
- 863 Planas, D., Veyer, D., Baidaliuk, A., Staropoli, I., Guivel-Benhassine, F., Rajah, M.M.,
864 Planchais, C., Porrot, F., Robillard, N., Puech, J., et al. (2021). Reduced sensitivity of SARS-
865 CoV-2 variant Delta to antibody neutralization. *Nature* 596, 276-280. 10.1038/s41586-021-
866 03777-9.
- 867 Rihn, S.J., Merits, A., Bakshi, S., Turnbull, M.L., Wickenhagen, A., Alexander, A.J.T., Baillie,
868 C., Brennan, B., Brown, F., Brunker, K., et al. (2021). A plasmid DNA-launched SARS-CoV-2
869 reverse genetics system and coronavirus toolkit for COVID-19 research. *PLOS Biology* 19,
870 e3001091. 10.1371/journal.pbio.3001091.
- 871 Roeder, A.J., Koehler, M.A., Svarovsky, S., Jasbi, P., Seit-Nebi, A., Gonzalez-Moa, M.J.,
872 Vanderhoof, J., Mckechnie, D., Edwards, B.A., and Lake, D.F. (2022). SARS-CoV-2
873 Omicron Variant Infection of Individuals with High Titer Neutralizing Antibodies Post-3rd
874 mRNA Vaccine Dose. *MedRxiv*. 10.1101/2022.03.03.22270812.

- 875 Rovida, F., Cassaniti, I., Paolucci, S., Percivalle, E., Sarasini, A., Piralla, A., Giardina, F.,
876 Sammartino, J.C., Ferrari, A., Bergami, F., et al. (2021). SARS-CoV-2 vaccine breakthrough
877 infections with the alpha variant are asymptomatic or mildly symptomatic among health care
878 workers. *Nature Communications* 12. 10.1038/s41467-021-26154-6.
- 879 Russell, M.W., and Mestecky, J. (2022). Mucosal immunity: The missing link in
880 comprehending SARS-CoV-2 infection and transmission. *Frontiers in Immunology* 13,
881 957107. 10.3389/fimmu.2022.957107.
- 882 Rydzynski Moderbacher, C., Ramirez, S.I., Dan, J.M., Grifoni, A., Hastie, K.M., Weiskopf, D.,
883 Belanger, S., Abbott, R.K., Kim, C., Choi, J., et al. (2020). Antigen-Specific Adaptive
884 Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease
885 Severity. *Cell* 183, 996-1012.e1019. 10.1016/j.cell.2020.09.038.
- 886 Scurr, M.J., Lippiatt, G., Capitani, L., Bentley, K., Lauder, S.N., Smart, K., Somerville, M.S.,
887 Rees, T., Stanton, R.J., Gallimore, A., et al. (2022). Magnitude of venous or capillary blood-
888 derived SARS-CoV-2-specific T cell response determines COVID-19 immunity. *Nature*
889 *Communications* 13. 10.1038/s41467-022-32985-8.
- 890 Selvavinayagam, S.T., Yong, Y.K., Tan, H.Y., Zhang, Y., Subramanian, G., Rajeshkumar,
891 M., Vasudevan, K., Jayapal, P., Narayanasamy, K., Ramesh, D., et al. (2022). Factors
892 Associated With the Decay of Anti-SARS-CoV-2 S1 IgG Antibodies Among Recipients of an
893 Adenoviral Vector-Based AZD1222 and a Whole-Virion Inactivated BBV152 Vaccine.
894 *Frontiers in Medicine* 9, 887974. 10.3389/fmed.2022.887974.
- 895 Sheikh-Mohamed, S., Isho, B., Chao, G.Y.C., Zuo, M., Cohen, C., Lustig, Y., Nahass, G.R.,
896 Salomon-Shulman, R.E., Blacker, G., Fazel-Zarandi, M., et al. (2022). Systemic and
897 mucosal IgA responses are variably induced in response to SARS-CoV-2 mRNA vaccination
898 and are associated with protection against subsequent infection. *Mucosal Immunology* 15,
899 799-808. 10.1038/s41385-022-00511-0.
- 900 Skelly, D.T., Harding, A.C., Gilbert-Jaramillo, J., Knight, M.L., Longet, S., Brown, A., Adele,
901 S., Adland, E., Brown, H., Chinnakannan, S., et al. (2021). Two doses of SARS-CoV-2
902 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern.
903 *Nature Communications* 12. 10.1038/s41467-021-25167-5.
- 904 Smoot, K., Yang, J., Tacker, D.H., Welch, S., Khodaverdi, M., Kimble, W., Wen, S., Amjad,
905 A., Marsh, C., Perrotta, P.L., and Hodder, S. (2022). Persistence and Protective Potential of
906 SARS-CoV-2 Antibody Levels After COVID-19 Vaccination in a West Virginia Nursing Home
907 Cohort. *JAMA Network Open* 5, e2231334. 10.1001/jamanetworkopen.2022.31334.
- 908 Sridhar, S., Begom, S., Bermingham, A., Hoschler, K., Adamson, W., Carman, W., Bean, T.,
909 Barclay, W., Deeks, J.J., and Lalvani, A. (2013). Cellular immune correlates of protection
910 against symptomatic pandemic influenza. *Nature Medicine* 19, 1305-1312.
911 10.1038/nm.3350.
- 912 Stærke, N.B., Reekie, J., Nielsen, H., Benfield, T., Wiese, L., Knudsen, L.S., Iversen, M.B.,
913 Iversen, K., Fogh, K., Bodilsen, J., et al. (2022). Levels of SARS-CoV-2 antibodies among
914 fully vaccinated individuals with Delta or Omicron variant breakthrough infections. *Nature*
915 *Communications* 13. 10.1038/s41467-022-32254-8.
- 916 Swadling, L., Diniz, M.O., Schmidt, N.M., Amin, O.E., Chandran, A., Shaw, E., Pade, C.,
917 Gibbons, J.M., Le Bert, N., Tan, A.T., et al. (2022). Pre-existing polymerase-specific T cells
918 expand in abortive seronegative SARS-CoV-2. *Nature* 601, 110-117. 10.1038/s41586-021-
919 04186-8.

- 920 Tarke, A., Coelho, C.H., Zhang, Z., Dan, J.M., Yu, E.D., Methot, N., Bloom, N.I., Goodwin,
921 B., Phillips, E., Mallal, S., et al. (2022). SARS-CoV-2 vaccination induces immunological T
922 cell memory able to cross-recognize variants from Alpha to Omicron. *Cell* 185, 847-
923 859.e811. 10.1016/j.cell.2022.01.015.
- 924 Tartof, S.Y., Slezak, J.M., Fischer, H., Hong, V., Ackerson, B.K., Ranasinghe, O.N.,
925 Frankland, T.B., Ogun, O.A., Zamparo, J.M., Gray, S., et al. (2021). Effectiveness of mRNA
926 BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the
927 USA: a retrospective cohort study. *The Lancet* 398, 1407-1416. 10.1016/s0140-
928 6736(21)02183-8.
- 929 Tay, M.Z., Rouers, A., Fong, S.W., Goh, Y.S., Chan, Y.H., Chang, Z.W., Xu, W., Tan, C.W.,
930 Chia, W.N., Torres-Ruesta, A., et al. (2022). Decreased memory B cell frequencies in
931 COVID-19 delta variant vaccine breakthrough infection. *EMBO Molecular Medicine* 14.
932 10.15252/emmm.202115227.
- 933 Torres, I., Bellido-Blasco, J.B., Gimeno, C., Burgos, J.S., Albert, E., Moya-Malo, R.,
934 Gascó-Laborda, J.C., Tornero, A., Soriano, J., Meseguer-Ferrer, N., et al. (2022a).
935 SARS-CoV-2 Delta-variant breakthrough infections in nursing home residents at midterm
936 after Comirnaty® COVID-19 vaccination. *Journal of Medical Virology* 94, 3776-3782.
937 10.1002/jmv.27799.
- 938 Torres, I., Giménez, E., Albert, E., Zulaica, J., Álvarez-Rodríguez, B., Burgos, J.S., Peiró, S.,
939 Limón, R., Vanaclocha, H., Rodado, C., et al. (2022b). SARS-CoV-2 Omicron BA.1 variant
940 breakthrough infections in nursing home residents after an homologous third dose of the
941 Comirnaty® COVID-19 vaccine: Looking for correlates of protection. *Journal of Medical*
942 *Virology* 94, 4216-4223. 10.1002/jmv.27867.
- 943 Tsang, T.K., Lam, K.-T., Liu, Y., Fang, V.J., Mu, X., Leung, N.H.L., Peiris, J.S.M., Leung,
944 G.M., Cowling, B.J., and Tu, W. (2022). Investigation of CD4 and CD8 T cell-mediated
945 protection against influenza A virus in a cohort study. *BMC Medicine* 20. 10.1186/s12916-
946 022-02429-7.
- 947 UK Health Security Agency (2021). SARS-CoV-2 variants of concern and variants under
948 investigation in England; Technical Briefing 31.
949 [https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_da](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1042367/technical_briefing-31-10-december-2021.pdf)
950 [ta/file/1042367/technical_briefing-31-10-december-2021.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1042367/technical_briefing-31-10-december-2021.pdf).
- 951 UK Health Security Agency (2022). COVID-19 vaccination: a guide to booster vaccination for
952 individuals aged 18 years and over and those aged 16 years and over who are at risk.
953 [https://www.gov.uk/government/publications/covid-19-vaccination-booster-dose-](https://www.gov.uk/government/publications/covid-19-vaccination-booster-dose-resources/covid-19-vaccination-a-guide-to-booster-vaccination-for-individuals-aged-18-years-and-over)
954 [resources/covid-19-vaccination-a-guide-to-booster-vaccination-for-individuals-aged-18-](https://www.gov.uk/government/publications/covid-19-vaccination-booster-dose-resources/covid-19-vaccination-a-guide-to-booster-vaccination-for-individuals-aged-18-years-and-over)
955 [years-and-over](https://www.gov.uk/government/publications/covid-19-vaccination-booster-dose-resources/covid-19-vaccination-a-guide-to-booster-vaccination-for-individuals-aged-18-years-and-over).
- 956 van den Brink, E.N., Ter Meulen, J., Cox, F., Jongeneelen, M.A., Thijssen, A., Throsby, M.,
957 Marissen, W.E., Rood, P.M., Bakker, A.B., Gelderblom, H.R., et al. (2005). Molecular and
958 biological characterization of human monoclonal antibodies binding to the spike and
959 nucleocapsid proteins of severe acute respiratory syndrome coronavirus. *Journal of Virology*
960 79, 1635-1644. 10.1128/JVI.79.3.1635-1644.2005.
- 961 Wall, E.C., Wu, M., Harvey, R., Kelly, G., Warchal, S., Sawyer, C., Daniels, R., Hobson, P.,
962 Hatipoglu, E., Ngai, Y., et al. (2021). Neutralising antibody activity against SARS-CoV-2
963 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination. *The Lancet* 397, 2331-2333.
964 10.1016/s0140-6736(21)01290-3.

965 Wei, J., Pouwels, K.B., Stoesser, N., Matthews, P.C., Diamond, I., Studley, R., Rourke, E.,
966 Cook, D., Bell, J.I., Newton, J.N., et al. (2022). Antibody responses and correlates of
967 protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines.
968 *Nature Medicine* 28, 1072-1082. [10.1038/s41591-022-01721-6](https://doi.org/10.1038/s41591-022-01721-6).

969 Zhou, D., Dejnirattisai, W., Supasa, P., Liu, C., Mentzer, A.J., Ginn, H.M., Zhao, Y.,
970 Duyvesteyn, H.M.E., Tuekprakhon, A., Nutalai, R., et al. (2021). Evidence of escape of
971 SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera. *Cell* 184, 2348-
972 2361.e2346. [10.1016/j.cell.2021.02.037](https://doi.org/10.1016/j.cell.2021.02.037).

973

974 **TABLE AND TABLE LEGEND**


975 **Table 1. Demographic characteristics of vaccine breakthrough cases**
 976 **compared to controls and factors associated with vaccine breakthrough in**
 977 **multivariable logistic regression analysis.**

	All (n=414)	Controls (n=378)	Cases (n=36)	OR ¹ (95% CI)	p value	Adjusted OR ² (95% CI)	p value
Age							
20-29	78 (18.8%)	70 (18.5%)	8 (22.2%)	1 (ref)	0.396	1 (ref)	0.456
30-39	86 (20.8%)	78 (20.6%)	8 (22.2%)	0.90 (0.31-2.56)		0.99 (0.34-2.86)	
40-49	109 (26.3%)	97 (25.7%)	12 (33.3%)	1.08 (0.43-2.89)		1.26 (0.49-3.44)	
50-59	97 (23.4%)	93 (24.6%)	4 (11.1%)	0.38 (0.10-1.24)		0.45 (0.11-1.51)	
60+	44 (10.6%)	40 (10.6%)	4 (11.1%)	0.88 (0.22-2.96)		1.19 (0.30-4.20)	
Sex							
Female	310 (74.9%)	280 (74.1%)	30 (83.3%)	1 (ref)	0.203	1 (ref)	0.078
Male	104 (25.1%)	98 (25.9%)	6 (16.7%)	0.57 (0.21-1.32)		0.46 (0.17-1.08)	
Ethnicity (self-reported)							
White	298 (84.4%)	270 (83.6%)	28 (93.3%)	1 (ref)	0.265	-	-
Asian	37 (10.5%)	36 (11.1%)	1 (3.3%)	0.27 (0.02-1.32)		-	
Other	18 (5.1%)	17 (5.3%)	1 (3.3%)	0.57 (0.03-2.93)		-	
Unreported	61	55	6	-		-	
BMI (kg/m²)							
Not obese (<30)	162 (89.5%)	150 (89.8%)	12 (85.7%)	1 (ref)	0.645	-	-
Obese (≥30.0)	19 (10.5%)	17 (10.2%)	2 (14.3%)	1.47 (0.22-6.01)		-	
Unreported	233	211	22	-		-	
Vaccine type							
BNT162b2	336 (81.2%)	310 (82.0%)	26 (72.2%)	1 (ref)	0.171	-	-
AZD1222	78 (18.8%)	68 (18.0%)	10 (27.8%)	1.75 (0.77-3.71)		-	
Infection history							
Naïve	244 (58.9%)	214 (56.6%)	30 (83.3%)	1 (ref)	0.001	1 (ref)	0.0009
Previous SARS-CoV-2	170 (41.1%)	164 (43.4%)	6 (16.7%)	0.26 (0.10-0.60)		0.25 (0.09-0.58)	

978 ¹Crude odds ratio derived from single logistic regression.


979 ²Adjusted odds ratio derived from multiple logistic regression. The final model included and adjusted for age, sex,
 980 and infection history.

981 FIGURES AND FIGURE LEGENDS



982 Figure 1. Study design and comparison of antibody and T cell responses
983 between cases and controls at 28 days after second vaccine dose.

984 **(A)** Schematic representation of study design including vaccination and
985 breakthrough infection time points. Created using Biorender.com. **(B)** Venn diagram
986 illustrating number of subjects with IgG and/or IFN γ ELISpot measurements, by
987 case/control status. **(C)** Ancestral SARS-CoV-2 spike- (S), receptor binding domain-
988 (RBD) and nucleoprotein- (N) specific IgG binding titre in cases (n=32) and controls
989 (n=200), as measured by MSD. Dashed lines represent threshold for positive
990 response (SARS-CoV-2 S IgG 1160 AU/mL, RDB IgG 1169 AU/mL, N IgG 3874
991 AU/mL). **(D)** Neutralising antibody (NAb) titres against ancestral (WT) and Delta
992 (B.1.617.2) isolates in a subset of cases (n=21) and controls (n=41) measured by live
993 virus microneutralisation (LV-MN) assay. Area between IC₅₀=40 and IC₅₀=2560
994 (dashed black lines) corresponds to the quantitative range of the assay. IC₅₀=5,
995 IC₅₀=10 and IC₅₀=5120 (solid grey lines) represent no, weak and complete
996 inhibition respectively. **(E)** T cell responses to peptide pools representing ancestral
997 SARS-CoV-2 S1, S2, total S (summation of S1 and S2 responses) and membrane
998 (M) and nucleoprotein (N) responses in cases (n=24) and controls (n=191), as
999 measured by IFN γ ELISpot assay. **(F)** Correlation between anti-S IgG titre, as
1000 measured by MSD, and total S T cell responses, as measured by IFN γ ELISpot, for
1001 all cases (n=24) and controls (n=144) where both parameters were measured.
1002 Dashed lines represent median value for each parameter. **(G)** Frequency of
1003 individuals with vaccine breakthrough (VB) in each quadrant of the graph in (F).
1004 Individuals are classified as having 'High' or 'Low' IgG and IFN γ responses on the
1005 basis of whether their response is above or below median for each variable. Number
1006 of cases and controls per group are shown below the graph. Values of 0 are
1007 replaced with 1 for representation on the logarithmic scale. Orange circles represent
1008 cases, blue circles represent controls. Bars represent median of each group (C-E).
1009 Error bars represent interquartile range (C-E) or 95% confidence interval (G). Two-
1010 tailed p-values derived from Mann-Whitney U tests (comparing cases to controls, (C-
1011 E)), Wilcoxon matched pairs signed rank tests (comparing WT and Delta responses,
1012 (D)) or pairwise Fisher's exact tests (G) shown above linking lines. For clarity, only
1013 adjusted p values <0.1 are shown in (G). Fold change in median response shown
1014 below linking lines or in brackets, calculated as median response for controls divided
1015 by median response for cases, or median response for Delta divided by median
1016 response for WT.



1017 **Figure 2. Comparison of memory B cell and T cell responses in a subset of**
 1018 **cases and matched controls at 28 days after second vaccine dose.**
 1019 **(A)** Venn diagram illustrating the overlapping subsets of cases and controls analysed
 1020 in (B-D). **(B)** Memory B cell responses against ancestral (WT) and Delta (B.1.617.2;
 1021 AY.1, AY.2, AY.3) SARS-CoV-2 spike (S) in a subset of cases (n=10) and matched
 1022 controls (n=11) measured by memory B cell IgG FluoroSpot. **(C)** Proportion of cells
 1023 expressing IFN γ , TNF or IL-2 in response to peptide pools representing ancestral
 1024 (WT) or Delta (B.1.617.2) spike in the CD4+ T cell population and **(D)** CD8+ T cell
 1025 population, in a subset of cases and matched controls (n=12 per group), as
 1026 as measured by intracellular cytokine staining (ICS) and flow cytometry. Populations

1027 were analysed by gating on single, live, CD3+ cells. Orange circles represent cases,
1028 blue circles represent controls. Bars represent median of each group. Error bars
1029 represent interquartile range. Paired data from the same individual are linked by grey
1030 lines. Two-tailed p-values derived from Mann-Whitney U tests (comparing cases to
1031 controls) or Wilcoxon matched pairs signed rank tests (comparing WT and Delta
1032 responses) shown above linking lines. Fold change in median response shown in
1033 brackets for comparisons where $p < 0.05$, calculated as median response for controls
1034 divided by median response for cases, or median response for Delta divided by
1035 median response for WT.